Prevention of hepatic stellate cell activation using JQ1- and atorvastatin-loaded chitosan nanoparticles as a promising approach in therapy of liver fibrosis.


Journal

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
ISSN: 1873-3441
Titre abrégé: Eur J Pharm Biopharm
Pays: Netherlands
ID NLM: 9109778

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 18 06 2018
revised: 09 10 2018
accepted: 20 11 2018
pubmed: 25 11 2018
medline: 23 4 2019
entrez: 25 11 2018
Statut: ppublish

Résumé

Preventing hepatic stellate cell (HSC) activation represents a promising approach to resolve liver fibrosis. Several drugs have been reported to delay/prevent HSCs activation, however with limited clinical benefits. The latter may be in part attributed to the limited ability of such drugs in targeting more than one pathway of HSC activation. Added to that, is their inability of reaching their target cell in sufficient amounts to induce a therapeutic effect. In this work, chitosan NPs were loaded with JQ1 and atorvastatin, two drugs that have been reported to prevent HSCs activation, however via different mechanisms. NPs were then modified with different densities of retinol (Rt) for active targeting of HSCs. The NP HSCs targeting ability as a function of Rt density was assessed in vitro on primary HSCs and in vivo in carbon tetrachloride (CCl

Identifiants

pubmed: 30471341
pii: S0939-6411(18)30764-1
doi: 10.1016/j.ejpb.2018.11.018
pii:
doi:

Substances chimiques

(+)-JQ1 compound 0
Acta2 protein, mouse 0
Actins 0
Azepines 0
Brd4 protein, mouse 0
Drug Carriers 0
Hydroxymethylglutaryl-CoA Reductase Inhibitors 0
Nuclear Proteins 0
Transcription Factors 0
Triazoles 0
Vitamin A 11103-57-4
Chitosan 9012-76-4
Atorvastatin A0JWA85V8F
Carbon Tetrachloride CL2T97X0V0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

96-106

Informations de copyright

Copyright © 2018. Published by Elsevier B.V.

Auteurs

Raghda Hassan (R)

Department of Pharmaceutical Technology, Faculty of Pharmacy & Biotechnology, The German University in Cairo (GUC), Cairo, Egypt.

Salma N Tammam (SN)

Department of Pharmaceutical Technology, Faculty of Pharmacy & Biotechnology, The German University in Cairo (GUC), Cairo, Egypt. Electronic address: salma.nabil@guc.edu.eg.

Sara El Safy (SE)

Department of Pharmaceutical Technology, Faculty of Pharmacy & Biotechnology, The German University in Cairo (GUC), Cairo, Egypt.

Mohammad Abdel-Halim (M)

Department of Pharmaceutical Chemistry, Faculty of Pharmacy & Biotechnology, The German University in Cairo (GUC), Cairo, Egypt.

Anastasia Asimakopoulou (A)

Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH University Hospital Aachen, Aachen, Germany.

Ralf Weiskirchen (R)

Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH University Hospital Aachen, Aachen, Germany.

Samar Mansour (S)

Department of Pharmaceutical Technology, Faculty of Pharmacy & Biotechnology, The German University in Cairo (GUC), Cairo, Egypt.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH